Abstract
Neoadjuvant chemotherapy (NAC) is increasingly used for treatment of early-stage breast cancer patients, with HR+, HER2- tumors showing the lowest rate of pathological complete response (pCR). Therefore, standardized tools result essential to identify those HR+, HER2- breast cancer patients with residual disease in the breast and/or axillary nodes who are at increased risk of distant recurrence after treatment with NAC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
